Advertisement Pharmaceutical Business review - Page 243 of 5288 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 1, 2026

Kazia closes oversubscribed offering to fund paxalisib’s clinical development

Kazia Therapeutics has closed an oversubscribed public offering that could provide the company with up to $120m in gross proceeds if all milestone-linked warrants are exercised, aimed primarily at funding clinical development of paxalisib.

Continue
Kazia’s other development programmes include EVT801, NDL2, and MSETC, with research underway across several solid tumour types. Credit: Zolnierek_photography / Shutterstock.com.
September 1, 2026

PharmaEssentia’s Besremi receives FDA approval for ET

Besremi may be prescribed for adults with ET regardless of genotype or disease status. Credit: 89stocker / Shutterstock.com.
August 31, 2026

Teva Pharmaceuticals to acquire BioXcel assets for up to $125m

BXCL501 is under US FDA review for possible at-home treatment of acute agitation in adults with schizophrenia. Credit: Tapati Rinchumrus/Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911
  2. AusperBio raises $120m to progress hepatitis B therapies
  3. FDA grants RPDD to ReviR’s RTX-117 for CMT
  4. ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy
  5. Jazz secures FDA approval for Ziihera in advanced HER2+ GEA

PRESS RELEASES

Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
Pharmaceutical Business Review
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography